- $64.37m
- -$50.66m
- $63.26m
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi
Fortress Biotech 2025 revenue rises, net loss narrows
U.S. STOCKS ON THE MOVE-Albemarle, Lowe's, nLIGHT
U.S. STOCKS ON THE MOVE-Cardinal Health, Decoy Therapeutic
Fortress Biotech jumps as FDA clears first rare pediatric disease treatment
US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease (updated)
US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease
Brief: Fortress Biotech And Cyprium Therapeutics Announce U.S. FDA Approval Of Zycubo® (Copper Histidinate), The First And Only Approved Treatment For Menkes Disease In The United States
Brief: Fortress Biotech, Cyprium Get FDA Acceptance for CUTX-101 NDA Resubmission
Brief: Fortress Biotech Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDA
Fortress Biotech Q3 revenue up 20.5%, Checkpoint sale nets $28 mln
Brief: Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
Brief: Fortress Biotech And Cyprium Therapeutics Announce An Update On The NDA For Cutx-101
US FDA declines to approve Fortress Bio and Zydus' treatment for a rare pediatric disease (updated)
Fortress tumbles as FDA declines to approve genetic disorder drug
US FDA declines to approve Fortress Bio and Zydus' treatment for a rare pediatric disease